Sangamo sees cash runway into 1Q26

As of September 30, 2025, we had cash and cash equivalents of $29.6 million, compared to cash and cash equivalents of $41.9 million as of December 31, 2024. Based on our current operating plan, we believe that our cash and cash equivalents as of September 30, 2025, together with the license fee received from Pfizer in October 2025 and the proceeds from sales of common stock under our at-the-market offering program since September 30, 2025, will be sufficient to fund our planned operations into the first quarter of 2026.